Why pay more attention to invasive fungal infection (IFI)?

Invasive fungal infection, or IFI for short, should be a concern to any health care provider who cares for critically ill patients. These diverse infections pose a serious threat to patients’ well-being, particularly those who are critically ill and/or immunosuppressed, and the number of IFIs has persisted over the past 2 decades, due in part to the widespread use of immunosuppressive therapies.1-4

This site provides an overview of these infections for the entire health care team, with a particular focus on team members who do not specialize in infectious diseases. Here you can also learn why appropriate stewardship of antifungal agents is so important, and explore ways to optimize transitions for patients moving from one care setting to another. Last but not least, My IFI provides you with resources that you can use to educate patients and their caregivers about these serious infections.

Click a heading below to find out more.

It's Important

IFI is more common than you may think
IFI can have a profound impact on patients
Advances in IFI care align with quality improvement goals

Feedback Survey

I rate this content:

This information makes me want to learn more about IFI.


1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. 

2. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.

3. Bennett JE. Introduction to mycoses. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015:2874-2878.

4. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175-191. 

5. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198-1208.

6. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041-1050.

7. Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health-Syst Pharm. 2009;66(19):1711-1717. https://www.ncbi.nlm.nih.gov/pubmed/19767376

8. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013.
https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed March 14, 2019.

9. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091-1100.

10. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101-1111.

11. Chang CC, Ananda-Rajah M, Belcastro A, et al. Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Intern Med J. 2014;44(12b):1389-1397.

12. Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract. 2008;14(4):189-193.

13. Hoenigl M, Duettmann W, Raggam RB, et al. Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. Int J Antimicrob Agents. 2014;44(2):140-144.

14. Institute for Healthcare Improvement. The IHI triple aim. http://www.ihi.org/engage/initiatives/tripleaim/pages/default.aspx. Accessed April 9, 2019.

15. Joint Commission. 2019 Hospital National Patient Safety Goals. https://www.jointcommission.org/assets/1/6/2019_HAP_NPSGs_final2.pdf. Accessed February 26, 2019. https://www.jointcommission.org/assets/1/6/2019_HAP_NPSGs_final2.pdf

16. Centers for Medicare & Medicaid Services. Eligible Hospital and Critical Access Hospital Medicaid EHR Incentive Program. Stage 3 Objectives and Measures. Table of Contents. Updated: August 2017. Accessed February 7, 2018.

17. Centers for Medicare & Medicaid Services. HCAHPS: patients' perspectives of 
care survey (12-21-2017). https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/HospitalHCAHPS.html. Accessed April 9, 2019.